Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease

The effects of aminoguanidine on hippocampal cytokines, amyloid beta, brain-derived neurotrophic factor, memory and oxidative stress status in chronically lipopolysaccharide-treated rats

INTRODUCTION

In the present study, the effects of aminoguanidine (AMG) on hippocampal cytokines, amyloid beta (Aβ), brain-derived neurotrophic factor, oxidative stress status and memory in chronically lipopolysaccharide (LPS) treated rats were investigated.

METHODS

The rats were divided into five groups and were treated: (1) Control (Saline), (2) LPS (1 mg/kg), (3-5) LPS- AMG50, LPS-AMG100, and LPS-AMG150 (AMG 50, 100 and 150 mg/kg 30 min before LPS injection). The treatment started five weeks prior to the behavioral experiments and continued during the behavioral tests (LPS injection two hours before each behavioral evaluation). Finally, the tissue was removed for biochemical measurements.

RESULTS

The escape latency in Morris water maze test and the latency to enter the dark compartment in passive avoidance test in LPS group were significantly greater than the control group (P < 0.001), while, in LPS-AMG 100 and LPS-AMG150 groups they were less than LPS group (P < 0.001). Malondialdehyde (MDA), NO metabolites of hippocampal and cortical tissues and interleukin-6 (IL-6), Aβ and tumor necrosis factor-α (TNFα) concentration in the hippocampus of LPS group were higher than control group (P < 0.001-P < 0.05). However, in LPS-AMG 100 and LPS-AMG150 group they were lower than LPS group (P < 0.001-P < 0.05). The thiol content and the activities of catalase (CAT) and superoxide dismutase (SOD) in both cortical and hippocampal tissues of LPS group were reduced compared to the control group (P < 0.001-P < 0.05). These factors enhanced in LPS-AMG 100 and LPS-AMG150 groups compared to LPS (P < 0.001-P < 0.05). The hippocampal content of brain-derived neurotrophic factor (BDNF) in LPS group was significantly lower compared to the control group (P < 0.001). All treated groups had higher BDNF content in comparison to LPS group (P < 0.01-P < 0.001).

CONCLUSION

The findings indicated that the protective effects of AMG against LPS-induced memory were accompanied by decreasing of inflammatory cytokines, Aβ, oxidative stress and increasing of anti-inflammatory mediators and BDNF.

The effect of CA1 administration of orexin-A on hippocampal expression of COX-2 and BDNF in a rat model of orofacial pain

ABSTRACT The neuropeptide orexin-A and its receptors are widely distributed in both hippocampal circuitry and pain transmission pathways. Objective: Involvement of the CA1 orexin 1 receptor (OX1R) on the modulation of orofacial pain and pain-induced changes in hippocampal expression of cyclooxygenase-2 (COX-2) and brain-derived neurotrophic factor (BDNF) was investigated. Methods: Orofacial pain was induced by an intra-lip injection of capsaicin (100 μg). Reverse transcription polymerase chain reaction and immunoblot analysis were used to indicate changes in hippocampal BDNF and COX-2 expression, respectively. Results: Capsaicin induces a significant pain response, which is not affected by either orexin-A or SB-334867-A, an OX1R antagonist. However, an increased expression of COX-2 and decreased expression of BDNF was observed in the hippocampus of animals that received capsaicin or SB-334867-A (80 nM) plus capsaicin. Meanwhile, orexin-A (40 pM) attenuated the effects of capsaicin on the expression of COX-2 and BDNF. Conclusions: CA1 OX1R activation moderates capsaicin-induced neuronal inflammation and neurotrophic deficiency.

Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease

OBJECTIVE

Previous studies suggest that the brain-derived neurotrophic factor (BDNF) Val66Met (rs6265) polymorphism may influence symptom onset in Alzheimer's disease (AD). Our recent cross-sectional findings suggest that Met66 may influence clinical expression in dominantly inherited AD (DIAD) through its effects on tau. However, it remains unclear whether carriage of Met66 in DIAD results in faster increases in cerebrospinal fluid (CSF) tau and ptau₁₈₁ , and whether these increases are associated with accelerated brain volume loss and memory decline.

METHODS

A total of 211 subjects (101 mutation noncarriers, 110 mutation carriers), who were cognitively normal, as defined by a Clinical Dementia Rating global score of 0, completed assessments of cognitive function, neuroimaging, and CSF sampling over 3.5 years as part of the Dominantly Inherited Alzheimer's Network.

RESULTS

In mutation carriers, Met66 carriers showed faster memory decline (4×), hippocampal volume loss (16×), and CSF tau and ptau₁₈₁ increases (6×) than Val66 homozygotes. BDNF did not influence rates of cortical β-amyloid accumulation or change in CSF Aβ₄₂ levels in mutation carriers. In mutation noncarriers, BDNF genotype had no effect on change in cognition, brain volume, cortical β-amyloid accumulation, or change in any CSF measures of tau, ptau₁₈₁ , and CSF Aβ₄₂ .

INTERPRETATION

As in sporadic AD, the deleterious effects of β-amyloid on cognitive function, brain volume loss, and CSF tau in DIAD mutation carriers are less in Val66 homozygotes. The BDNF Val66Met polymorphism should be considered as a potential moderator of clinical trial outcomes in current treatment and prevention trials in DIAD and sporadic AD. Ann Neurol 2018;84:424-435.

Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits

Misfolded and hyperphosphorylated tau accumulates in several neurodegenerative disorders including Alzheimer's disease, frontotemporal dementia with Parkinsonism, corticobasal degeneration, progressive supranuclear palsy, Down syndrome, and Pick's disease. Tau is a microtubule-binding protein, and its role in microtubule stabilization is well defined. In contrast, while growing evidence suggests that tau is also involved in synaptic physiology, a complete assessment of tau function in the adult brain has been hampered by robust developmental compensation of other microtubule-binding proteins in tau knockout mice. To circumvent these developmental compensations and assess the role of tau in the adult brain, we generated an adeno-associated virus (AAV) expressing a doxycycline-inducible short-hairpin (Sh) RNA targeted to tau, herein referred to as AAV-ShRNATau. We performed bilateral stereotaxic injections in 7-month-old C57Bl6/SJL wild-type mice with either the AAV-ShRNATau or a control AAV. We found that acute knockdown of tau in the adult hippocampus significantly impaired motor coordination and spatial memory. Blocking the expression of the AAV-ShRNATau, thereby allowing tau levels to return to control levels, restored motor coordination and spatial memory. Mechanistically, the reduced tau levels were associated with lower BDNF levels, reduced levels of synaptic proteins associated with learning, and decreased spine density. We provide compelling evidence that tau is necessary for motor and cognitive function in the adult brain, thereby firmly supporting that tau loss-of-function may contribute to the clinical manifestations of many tauopathies. These findings have profound clinical implications given that anti-tau therapies are in clinical trials for Alzheimer's disease.

Lactuca capensis reverses memory deficits in Aβ1-42-induced an animal model of Alzheimer's disease

We investigated the neuropharmacological effects of the methanolic extract from Lactuca capensis Thunb. leaves (100 and 200 mg/kg) for 21 days on memory impairment in an Alzheimer's disease (AD) rat model produced by direct intraventricular delivery of amyloid‐β1‐42 (Aβ1‐42). Behavioural assays such as Y‐maze and radial arm maze test were used for assessing memory performance. Aβ1‐42 decreased cognitive performance in the behavioural tests which were ameliorated by pre‐treatment with the methanolic extract. Acetylcholinesterase activity and oxidant–antioxidant balance in the rat hippocampus were abnormally altered by Aβ1‐42 treatment while these deficits were recovered by pre‐treatment with the methanolic extract. In addition, rats were given Aβ1‐42 exhibited in the hippocampus decreased brain‐derived neurotrophic factor (BDNF) mRNA copy number and increased IL‐1β mRNA copy number which was reversed by the methanolic extract administration. These findings suggest that the methanolic extract could be a potent neuropharmacological agent against dementia via modulating cholinergic activity, increasing of BDNF levels and promoting antioxidant action in the rat hippocampus.